Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma.

Authors :: Liu Y
Yan F
Jiang VC
Li Y
Che Y
McIntosh J
Jordan A
Hou I
Nie L
Jin J
Wang W
Lee HH
Yao Y
Wang M
Source :: Haematologica [Haematologica] 2023 May 01; Vol. 108 (5), pp. 1412-1416. Date of Electronic Publication: 2023 May 01.
Publication Year :: 2023

Subjects :: Adult
Humans
Immunotherapy, Adoptive
Cell- and Tissue-Based Therapy
Lymphoma, Mantle-Cell pathology
Receptors, Chimeric Antigen

Full Text Access

Tools